The next generation of vaccines for the treatment of cancer

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 1, 1999, Pages 57-63

  Long, Li ^a   Glover, Robert T ^a   Kaufman, Howard L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; TUMOR ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ANTIGEN EXPRESSION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DRUG TARGETING; FEMALE; FOWLPOX VIRUS; GENE EXPRESSION; HUMAN; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; REVIEW; TUMOR REJECTION; VACCINIA VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD80; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CLINICAL TRIALS; FEMALE; GENETIC VECTORS; HUMANS; MALE; NEOPLASMS; VACCINIA VIRUS;

FOWLPOX VIRUS; VACCINIA; VACCINIA VIRUS;

EID: 0032933604     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Hellstrom l, Hellstrom K, Sjogren H, Warner G: Demonstration of cell-mediated Immunity to human neoplasms of various histological types. Int J Cancer (1971) 7:1-16.
2. Rosenberg S, Kawakami Y, Robbins P, Wang R: Identification of the genes encoding cancer antigens: Implications for cancer Immunotherapy. Adv Cancer Res (1996) 70:145-177.
3. Mackett M, Smith G, Moss B: Vaccinia virus: A selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA (1982) 79:7415-7419. Describes the general ability to utilize vaccinia virus as an expression vector.
4. Mackett M, Smith G, Moss B: General method for production and selection of Infectious vaccinia virus recombinants expressing foreign genes. J Virol (1984) 49:857-564. Describes the methodology for constructing recomlnant vaccinia virus vectors.
5. Kantor J, Irvine K, Abrams S, Kaufman H, Dipletro J, Schlom J: Antitumor activity and immune responses Induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst (1992) 84:1084-1091.
6. McAneny D, Ryan CA, Beazley RM, Kaufman HL: Results of a phase I trial of a recombinant vaccinia virus that expresses carclnoembryonic antigen In patients with advanced colorectal cancer. Ann Surg Oncol (1996) 3:495-500.
7. Tsang K, Zaremba S, Nieroda C, Zhu M, Hamilton J, Schlom J: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients Immunized with recombinant vaccinla-CEA vaccine. J Natl Cancer Inst (1995) 87:982-990. The first report of CTL against CEA in cancer patients vaccinated with a recombinant vaccinia-CEA virus.
8. Fenner F, Henderson D, Arita I, Jezek Z, Ladnyi I. Smallpox and its eradication. Geneva: WHO 1988.
9. Estin C, Stevenson U, Plowman G, Hu S, Sridhar P, Hellstrom I, Brown J, Hellstrom K: Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use In Immunotherapy. Proc Natl Acad Sci USA (1988) 85:1052-1056.
10. McKenzie S, Destree A, Gordon E, Panlcali D, Bernards R, Weinberg R: Induction of antitumor immunity by Immunization with a vaccinia virus vector expressing an oncogene-encoded product Vaccines (1988) 88:19-23.
11. Kaufman H, Schlom J, Kantor J: A recombinant vaccinia virus expressing human carcinoembryonic antigen. Int J Cancer (1991) 48:900-907.
12. Kantor J, Irvine K, Abrams S, Snoy P, Olsen R, Greiner J, Kaufman H, Eggensperger D, Schlom J: Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene In a nonhuman primate. Cancer Res (1992) 52:6917-6925.
13. Kaufman H, Long L, Horig H: The current status of cancer vaccines. (Review). Einstein Quart J Biol Med (1998) 15:3-23.
14. Moss B: Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA (1996) 93:11341-11348. General review of the status of recombinant vaccinia virus applications.
15. Paoletti E: Applications of pox virus vectors to vaccination: An update. Proc Natl Acad Sci USA (1996) 93:11349-11353. General review of the status of non-replicating poxvirus vaccines.
16. Tartaglia J, Perkus M, Taylor J, Norton E, Audonnet J, Cox W, Davis S, van der Hoeven J, Melgnier B, Riviere M, Languet B, Paoletti E: NYVAC: A highly attenuated strain of vaccinia virus. Virology (1992) 188:217-232.
17. Lanar D, Tine J, de Taisne C, seguin M, Cox W, Winstow J, Ware L, Kauffman E, Gordon D, Ballou W, Paoletti E, Sadoff J: Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect Immun (1996) 64:1666-1671.
18. Ockenhouse C, Sun P, Lanar D, Wellde B, Hall B, Kester K, Stoute J, Magill A, Krzych U, Farley L, Wirtz R, Sadoff J, Kaslow D, Kumar S, Church L, Crutcher J, Wizel B, Hoffman S, Lalvani A, Hill A, Tine J, Guito K, de Taisne C, Anders R, Ballou W: Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multlantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis (1998) 177:1664-1673.
19. Mahnel H, Mayr A: Erfahrungen bei der schutzimpfung gegen orthopocken von mensch und tier mit dem Impfstamm MVA. Bert Münch Tierarzt Wschr (1994) 107:253-256.
20. Mayr A, Hochstein-Mintzel V, Stickl H: Abstrammung, elgenschaftenund verwendung des attenuierten vacciniastammes MVA. Infection (1975) 3:6-16.
21. Carroll M, Moss B: Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology (1997) 238:198-211.
22. Bender B, Rowe C, Taylor S, Wyatt L, Moss B, Small PJ: Oral Immunization with a replication-deficient recombinant vaccinia virus protects mice against Influenza. J Virol (1996) 70:6418-6424.
23. Hirsch V, Fuerst T, Sutter G, Carroll M, Yang L, Goldstein S, Piatak MJ, Elkins W, Alvord W, Montefiori D, Moss B, Lifson J: Patterns of viral replication correlate with outcome In simian Immunodeficiency virus (SIV)-Infected macaques: Effect of prior Immunization with a trivalent SIV vaccine In modified vaccinia virus Ankara. J Virol (1996) 70:3741-3752.
24. Wang M, Bronte V, Chen P, Gritz L, Panicall D, Rosenberg S, Restifo N: Active immunotherapy of cancer with a nonrepilcating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 154:4685-4692.
25. Taylor J, Paoletti E: Fowlpox virus as a vector In non-avian species. Vaccine (1988) 6:466-468.
26. Taylor J, Trimarchi C, Weinberg R, Languet B, Guillemin F, Desmettre P, Paoletti E: Efficacy studies on canarypoxrables recombinant virus. Vaccine (1991) 9:190-193.
27. Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, Paoletti E, Plotkin S: Immunisation with canarypox virus expressing rabies glycoprotein. Lancet (1992) 339:1429-1432.
28. Fries L, Tartaglia J, Taylor J, Kauffman E, Meignier B, Paotettl E, Plotkin S: Human safety and Immunogenicity of a canarypoxrabies glyeoprotein recombinant vaccine: An alternative poxvirus vector system. Vaccine (1996) 14:428-434.
29. Clements-Mann M, Weinhold K, Matthews T, Graham B, Gorse G, Keefer M, McElrath M, Hsieh R, Mestecky J, Zolla-Pazner S, Mascola J, Schwartz D, Slliciano R, Corey L, Wright P, Belshe R, Dolin R, Jackson S, Xu S, Fast P, Walker M, Stablein D, Excler J, Tartaglia J, Duliege A, Sinangil F, Paoletti E: Immune responses to human immunodeficiency virus (HIV) type 1 Induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines In seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 177:1230-1246.
30. Marshall J, Hawkins M, Tsang K, Richmond E, Pedicano J, Zhu M, Schlom J: A phase I study In cancer patients of a replication defective avipox (ALVAC) recombinant vaccine that expresses human carcinoembryonic antigen (CEA). J Clin Oncol (1999) in press.
31. Gold P, Freedman S: Demostration of tumor-specific antigens In human colon carcinoma by Immunological tolerance and absorption techniques. J Exp Med (1965) 121:439-462. Describes the isolation and characterzation of CEA.
32. Goldenberg D, Sharkey R, Primus F: Carcinoembryonic antigen In histopathology: Immunoperoxidase staining of conventional tissue sections. J Natl Cancer Inst (1976) 57:11-22.
33. Nap M, Moilgard K, Burtin P, Reuren G: Immunohistochemistry of carcinoembryonic antigen In the embryo, fetus, and adult Tumour Biol (1988) 9:145-153.
34. Konstadoulakis M, Syrigos K, Albanopoulos C, Mayers G, Golematis B: The presence of anti-carcinoembryonic antigen (CEA) antibodies In the sera of patients with gastrointestinal malignancies. J Clin Immunol (1994) 14:310-313
35. Alters S, Gadea J, Philip R: Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells. Adv Exp Med Biol (1997) 417:519-524.
36. Alters S, Gadea J, Sorich M, O'Donoghue G, Talib S, Philip R: Dendritic cells pulsed with CEA peptide Induce CEA-specific CTL with restricted TCR repertoire. J Immunother (1998) 21: 17-26. Evidence for generation of CTLs that recognize CEA-expressing tumor cells in an HLA restricted manner is shown after immunizing with CEA peptide-pulsed dendritic cells.
37. Hodge JW, McLaughlin JP, Kantor JA, Schlom J: Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine (1997) 15:759-768.
38. Conry R, LoBugilo A, Curiel D: Phase la trial of a polynucleotide anti-tumor immunization to human carcinoembryonic antigen In patients with metastatic colorectal cancer. Hum Gene Ther (1996) 7:755.
39. Fagerberg J, Samanci A, Yi O, Strigard K, Frodin J, Wahren B, Ruden U, Mellstedt H: Recombinant carcinoembryonic antigen and granulocyte-macrophage colony-stimulating factor for active Immunization of colorectal carcinoma patients. J Immunother (1995) 18:132.
40. Bratscher P: The two-signal modal of lymphocyte activation twenty-one years later. Immunol Today (1992) 13:74-76.
41. June C, Bluestone J, Nadler L, Thompson C: The B7 and CD28 receptor families. Immunol Today (1994) 15:321-331. General review of the B7 family and its interaction with CD28-activated T-lymphocyte
42. Fallarino F, Fields P, Gajewski T: B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation In the absence of CD28. J Exp Med (1998) 188:205-210.
43. Gimmi C, Freeman G, Gribben J, Gray G, Nadier L: Human T-cell cional energy Is induced by antigen presentation In the absence of B7 costimulation. Proc Natl Acad Sci USA (1993) 90:6586-6590.
44. La Motte R, Rubin M, Barr E, Leiden J, Bluestone J, Mokyr M: Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 co-stimulatory molecule. Cancer Immunol Immunother (1996) 42:161-169.
45. Yu X, Abe R, Hodes R: The role of B7-CD28 co-stimulation In tumor rejection. Int Immun (1998) 10:791-797.
46. Chamberlain R, Carroll M, Bronte V, Hwu P, Warren S, Yang J, Nishimura M, Moss B, Rosenberg S, Restifo N: Costimulation enhances the active Immunotherapy effect of recombinant anti-cancer vaccines. Cancer Res (1996) 56:2832-2836.
47. Akagi J, Hodge J, McLaughlin J, Gritz L, Mazara G, Kufe D, Schlom J, Kantor J: Therapeutic antitumor response after Immunization with an admixture of recombinant vaccinia virus expressing a modified MUC-1 gene and the murine T-cell costimulatory molecule B7. J Immunother (1997) 20:38-47.
48. Hodge J, McLaughlin J, Abrams S, Shupert L, Schlom J, Kantor J: Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results In enhanced specific T-cell responses and antitumor Immunity. Cancer Res (1995) 55:3598-3603.
49. Chong H, Hutchinson G, Hart I, Vile R: Expression of B7 costimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but inuces T-cell-dependent systemic immunity only against B7-expressing tumours. Br J Cancer (1998) 78:1043-1050.
50. Wu T-C, Huang A, Jaffee E, Levitsky H, Pardoll D: A reassessment of the role of B7-1 expression In tumor rejection. J Exp Med (1995) 182:1415-1421.
51. Morgan D, Kreuwel H, Fleck S, Levitsky H, Pardoll D, Sherman L: Activation of low avidity CTL specific for a self epitope results In tumor rejection but not autoimmunlty. J Immunol (1998)160:643-651. Describes a transgenic animal model that can elicit tumor-specific CTL responses without generating autoimmunity to 'self' tumor antigen.